Bristol-Myers Squibb wins antitrust approval to buy Celgene on condition it sell psoriasis drug

Bristol-Myers Squibb Co and Celgene Corp have won U.S. antitrust approval for their merger on condition that they sell Celgene's psoriasis drug Otezla, the Federal Trade Commission said in a statement on Friday.